Brief: OSE Immunotherapeutics: First Patient Randomized In Phase 2 Clinical Trial Of Tedopi
26/08/2021 17:02
Aug 26 (Reuters) - Ose Immunotherapeutics SA OSE.PA :
* OSE IMMUNOTHERAPEUTICS AND ARCAGY-GINECO ANNOUNCE FIRST
PATIENT
RANDOMIZED IN PHASE 2 CLINICAL TRIAL EVALUATING TEDOPI® IN
COMBINATION WITH PEMBROLIZUMAB IN OVARIAN CANCER
* CLINICAL TRIAL SPONSORED AND CONDUCTED BY FRENCH ONCOLOGY
COOPERATIVE GROUP ARCAGY-GINECO AND SUPPORTED BY MERCK SHARP &
DOHME CORP. (MSD)
* FIRST RESULTS EXPECTED BEGINNING OF 2025
* THREE ARM TEDOVA STUDY AIMS AT EVALUATING
NEO-EPITOPE-BASED
VACCINE TEDOPI AS A MAINTENANCE TREATMENT, ALONE OR IN
COMBINATION
Source text for Eikon: ID:nGNXbWBgkt
Further company coverage: OSE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO